Bacteriophage LM33_P1, a fast-acting weapon against the pandemic ST131-O25b: H4 Escherichia coli clonal complex

Journal of Antimicrobial Chemotherapy

Volumn 71, Issue 11, 2016, Pages 3072-3080

  Dufour, Nicolas ^a,b,d,f   Clermont, Olivier ^b,d   La Combe, Beatrice ^a,b,d   Messika, Jonathan ^a,b,d   Dion, Sara ^b,d   Khanna, Varun ^e   Denamur, Erick ^b,c,d   Ricard, Jean Damien ^a,b,d   Debarbieux, Laurenton ^f   Eveillard, M ^g   Kouatchet, A ^g   Lasocki, S ^g   Asfar, P ^g   Billard Pomares, T ^a   Magdoud, F ^a   Barnaud, G ^a   Corvec, S ^h   Lakhal, K ^h   Armand, L ⁱ   Wolff, M ⁱ   Bourdon, S ^j   Reignier, J ^j   Martin, S ^j   Fihman, V ^k   Deprost, N ^k   Bador, J ^l   Charles, P E ^l   Goret, J ^m   Boyer, A ^m   Wallet, F ⁿ   Jaillette, E ⁿ   Nseir, S ⁿ   Landraud, L ^o   Ruimy, R ^o   Danin, P E ^o   Dellamonica, J ^o   Cremniter, J ^p   Frat, J P ^p   Jaureguy F ^q   Clec'h, C ^q   Decre D ^r   Maury, E ^r   more..

^a HÔPITAL LOUIS MOURIER   (France)

^b UNIVERSITÉ PARIS DIDEROT   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e CNRS   (France)

^f INSTITUT PASTEUR   (France)

^g ANGERS UNIVERSITY HOSPITAL   (France)

^h NANTES UNIVERSITY HOSPITAL   (France)

ⁱ BICHAT HOSPITAL   (France)

^j La Roche sur Yon   (France)

^k HENRI MONDOR HOSPITAL   (France)

^l DIJON UNIVERSITY HOSPITAL   (France)

^m BORDEAUX UNIVERSITY HOSPITAL   (France)

ⁿ LILLE UNIVERSITY HOSPITAL   (France)

^o UNIVERSITY HOSPITAL OF NICE   (France)

^p POITIERS UNIVERSITY HOSPITAL   (France)

^q CHU Avicenne Bobigny   (France)

^r HÔPITAL SAINT ANTOINE   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BACTERIOPHAGE LM33 P1; EXOPOLYSACCHARIDE; LIPOPOLYSACCHARIDE; O ANTIGEN; UNCLASSIFIED DRUG;

ADSORPTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL LOAD; BACTERIAL STRAIN; BACTERIOPHAGE; BIOCHEMISTRY; CONTROLLED STUDY; DOSE RESPONSE; DRUG BINDING; DRUG EFFECT; DRUG EFFICACY; DRUG SPECIFICITY; ESCHERICHIA COLI; GENE SEQUENCE; GENETICS; IMMUNOLOGY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PANDEMIC; PNEUMONIA; PODOVIRIDAE; SEPTICEMIA; SINGLE DRUG DOSE; URINARY TRACT INFECTION; VIRION; VIROLOGY; ANIMAL; CLASSIFICATION; COLIPHAGE; DISEASE MODEL; DNA SEQUENCE; ESCHERICHIA COLI INFECTIONS; GENOTYPE; GROWTH, DEVELOPMENT AND AGING; ISOLATION AND PURIFICATION; MICROBIAL VIABILITY; MICROBIOLOGY; PHAGE THERAPY; PHYSIOLOGY; PROCEDURES; VIRUS GENOME;

ANIMALS; COLIPHAGES; DISEASE MODELS, ANIMAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; GENOME, VIRAL; GENOTYPE; MICE; MICROBIAL VIABILITY; PHAGE THERAPY; SEQUENCE ANALYSIS, DNA;

EID: 84994508106     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkw253     Document Type: Article

References (66)

1. Tenaillon O, Skurnik D, Picard B et al. The population genetics of commensal Escherichia coli. Nat Rev Microbiol 2010; 8: 207-17.
2. Nicolas-Chanoine MH, Bertrand X, Madec JY. Escherichia coli ST131, an intriguing clonal group. Clin Microbiol Rev 2014; 27: 543-74.
3. Rogers BA, Sidjabat HE, Paterson DL. Escherichia coli O25b-ST131: a pandemic, multiresistant, community-associated strain. J Antimicrob Chemother 2011; 66: 1-14.
4. Russo TA, Johnson JR. Proposal for a new inclusive designation for extraintestinal pathogenic isolates of Escherichia coli: ExPEC. J Infect Dis 2000; 181: 1753-4.
5. Picard B, Garcia JS, Gouriou S et al. The link between phylogeny and virulence in Escherichia coli extraintestinal infection. Infect Immun 1999; 67: 546-53.
6. Mora A, Dahbi G, Lopez C et al. Virulence patterns in a murine sepsis model of ST131 Escherichia coli clinical isolates belonging to serotypes O25b:H4 and O16:H5 are associated to specific virotypes. PLoS One 2014; 9: e87025.
7. Johnson JR, Porter SB, Zhanel G et al. Virulence of Escherichia coli clinical isolates in a murine sepsis model in relation to sequence type ST131 status, fluoroquinolone resistance, and virulence genotype. Infect Immun 2012; 80: 1554-62.
8. Peirano G, Bradford PA, Kazmierczak KM et al. Global incidence of carbapenemase-producing Escherichia coli ST131. Emerg Infect Dis 2014; 20: 1928-31.
9. Coque TM, Novais A, Carattoli A et al. Dissemination of clonally related Escherichia coli strains expressing extended-spectrum b-lactamase CTX-M-15. Emerg Infect Dis 2008; 14: 195-200.
10. Nicolas-Chanoine MH, Blanco J, Leflon-Guibout V, et al. Intercontinental emergence of Escherichia coli clone O25:H4-ST131 producing CTX-M-15. J Antimicrob Chemother 2008; 61: 273-81.
11. Hasman H, Hammerum AM, Hansen F et al. Detection of mcr-1 encoding plasmid-mediated colistin-resistant Escherichia coli isolates from human bloodstream infection and imported chicken meat, Denmark 2015 Euro Surveill 2015; 20: pii=30085.
12. Colomer-Lluch M, Mora A, Lopez C et al. Detection of quinolone-resistant Escherichia coli isolates belonging to clonal groups O25b:H4-B2-ST131 and O25b:H4-D-ST69 in raw sewage and river water in Barcelona, Spain. J Antimicrob Chemother 2013; 68: 758-65.
13. Reardon S. Phage therapy gets revitalized. Nature 2014; 510: 15-6.
14. Lefort A, Panhard X, Clermont O et al. Host factors and portal of entry outweigh bacterial determinants to predict the severity of Escherichia coli bacteremia. J Clin Microbiol 2011; 49: 777-83.
15. Messika J, Magdoud F, Clermont O et al. Pathophysiology of Escherichia coli ventilator-associated pneumonia: implication of highly virulent extraintestinal pathogenic strains. Intensive Care Med 2012; 38: 2007-16.
16. Massot M, Daubie AS, Clermont O et al. Phylogenetic, virulence and antibiotic resistance characteristics of commensal strain populations of Escherichia coli from community subjects in the Paris area in 2010 and evolution over 30 years. Microbiology 2016; 162: 642-50.
17. Johnson JR, Clermont O, Johnston B et al. Rapid and specific detection, molecular epidemiology, and experimental virulence of the O16 subgroup within Escherichia coli sequence type 131. J ClinMicrobiol 2014; 52: 1358-65.
18. Clermont O, Olier M, Hoede C et al. Animal and human pathogenic Escherichia coli strains share common genetic backgrounds. Infect Genet Evol 2011; 11: 654-62.
19. Clermont O, Christenson JK, Daubie AS et al. Development of an allele-specific PCR for Escherichia coli B2 sub-typing, a rapid and easy to perform substitute of multilocus sequence typing. J Microbiol Methods 2014; 101: 24-7.
20. Ochman H, Selander RK. Standard reference strains of Escherichia coli from natural populations. J Bacteriol 1984; 157: 690-3.
21. Clermont O, Christenson JK, Denamur E et al. The Clermont Escherichia coli phylo-typing method revisited: improvement of specificity and detection of new phylo-groups. Environ Microbiol Rep 2013; 5: 58-65.
22. Clermont O, Gordon D, Denamur E. A guide to the various phylogenetic classification schemes for Escherichia coli and the correspondence among schemes. Microbiology 2015; 161: 980-8.
23. Clermont O, Johnson JR, Menard M et al. Determination of Escherichia coli O types by allele-specific polymerase chain reaction: application to the O types involved in human septicemia. Diagn Microbiol Infect Dis 2007; 57: 129-36.
24. Szijarto V, Lukasiewicz J, Gozdziewicz TK et al. Diagnostic potential of monoclonal antibodies specific to the unique O-antigen of multidrugresistant epidemic Escherichia coli clone ST131-O25b:H4. Clin Vaccine Immunol 2014; 21: 930-9.
25. Van Twest R, Kropinski AM. Bacteriophage enrichment from water and soil. Methods Mol Biol 2009; 501: 15-21.
26. Boulanger P. Purification of bacteriophages and SDS-PAGE analysis of phage structural proteins from ghost particles. Methods Mol Biol 2009; 502: 227-38.
27. Saussereau E, Vachier I, Chiron R et al. Effectiveness of bacteriophages in the sputum of cystic fibrosis patients. Clin Microbiol Infect 2014; 20: O983-90.
28. Davis MR Jr, Goldberg JB. Purification and visualization of lipopolysaccharide from Gram-negative bacteria by hot aqueous-phenol extraction. J Vis Exp 2012; (63): pii=3916.
29. Hyman P, Abedon ST. Practical methods for determining phage growth parameters. Methods Mol Biol 2009; 501: 175-202.
30. Vallenet D, Belda E, Calteau A et al. MicroScope-an integrated microbial resource for the curation and comparative analysis of genomic and metabolic data. Nucleic Acids Res 2013; 41: D636-47.
31. Aziz RK, Bartels D, Best AA et al. The RAST Server: rapid annotations using subsystems technology. BMC Genomics 2008; 9: 75.
32. Dufour N, Debarbieux L, Fromentin M et al. Treatment of highly virulent extraintestinal pathogenic Escherichia coli pneumonia with bacteriophages. Crit Care Med 2015; 43: e190-8.
33. Vimont S, Boyd A, Bleibtreu A et al. The CTX-M-15-producing Escherichia coli clone O25b: H4-ST131 has high intestine colonization and urinary tract infection abilities. PLoS One 2012; 7: e46547.
34. Johnson JR, Tchesnokova V, Johnston B et al. Abrupt emergence of a single dominant multidrug-resistant strain of Escherichia coli. J Infect Dis 2013; 207: 919-28.
35. Scholl D, Merril C. The genome of bacteriophage K1F, a T7-like phage that has acquired the ability to replicate on K1 strains of Escherichia coli. J Bacteriol 2005; 187: 8499-503.
36. Kajsik M, Oslanecova L, Szemes T et al. Characterization and genome sequence of Dev2, a new T7-like bacteriophage infecting Cronobacter turicensis. Arch Virol 2014; 159: 3013-9.
37. Steven AC, Trus BL, Maizel JV et al. Molecular substructure of a viral receptor-recognition protein. The gp17 tail-fiber of bacteriophage T7. J Mol Biol 1988; 200: 351-65.
38. Casjens SR, Molineux IJ. Short noncontractile tail machines: adsorption and DNA delivery by podoviruses. Adv Exp Med Biol 2012; 726: 143-79.
39. Kelley LA, Mezulis S, Yates CM et al. The Phyre2 web portal for protein modeling, prediction and analysis. Nat Protoc 2015; 10: 845-58.
40. Adams MH, Park BH. An enzyme produced by a phage-host cell system. II. The properties of the polysaccharide depolymerase. Virology 1956; 2: 719-36.
41. Szijarto V, Guachalla LM, Visram ZC et al. Bactericidal monoclonal antibodies specific to the lipopolysaccharide O antigen frommultidrug-resistant Escherichia coli clone ST131-O25b:H4 elicit protection in mice. Antimicrob Agents Chemother 2015; 59: 3109-16.
42. Manges AR, Johnson JR, Foxman B et al. Widespread distribution of urinary tract infections caused by a multidrug-resistant Escherichia coli clonal group. N Engl J Med 2001; 345: 1007-13.
43. Riley LW. Pandemic lineages of extraintestinal pathogenic Escherichia coli. Clin Microbiol Infect 2014; 20: 380-90.
44. Khan Mirzaei M, Nilsson AS. Isolation of phages for phage therapy: a comparison of spot tests and efficiency of plating analyses for determination of host range and efficacy. PLoS One 2015; 10: e0118557.
45. Abedon ST. Lysis from without. Bacteriophage 2011; 1: 46-9.
46. Heineman RH, Bull JJ. Testing optimality with experimental evolution: lysis time in a bacteriophage. Evolution 2007; 61: 1695-709.
47. Nguyen HM, Kang C. Lysis delay and burst shrinkage of coliphage T7 by deletion of terminator Tphi reversed by deletion of early genes. J Virol 2014; 88: 2107-15.
48. Bayer ME. Adsorption of bacteriophages to adhesions between wall and membrane of Escherichia coli. J Virol 1968; 2: 346-56.
49. Olkkonen VM, Bamford DH. Quantitation of the adsorption and penetration stages of bacteriophage phi 6 infection. Virology 1989; 171: 229-38.
50. Puck TT, Garen A, Cline J. The mechanism of virus attachment to host cells. I. The role of ions in the primary reaction. J Exp Med 1951; 93: 65-88.
51. Storms ZJ, Smith L, Sauvageau D et al. Modeling bacteriophage attachment using adsorption efficiency. Biochem Engineering J 2012; 64: 22-9.
52. De Paepe M, Taddei F. Viruses' life history: towards a mechanistic basis of a trade-off between survival and reproduction among phages. PLoS Biol 2006; 4: e193.
53. Labrie SJ, Samson JE, Moineau S. Bacteriophage resistance mechanisms. Nat Rev Microbiol 2010; 8: 317-27.
54. Jann K, Jann B. Polysaccharide antigens of Escherichia coli. Rev Infect Dis 1987; 9 Suppl 5: S517-26.
55. Whitfield C. Biosynthesis and assembly of capsular polysaccharides in Escherichia coli. Annu Rev Biochem 2006; 75: 39-68.
56. Pires DP, Oliveira H, Melo LD et al. Bacteriophage-encoded depolymerases: their diversity and biotechnological applications. Appl Microbiol Biotechnol 2016; 100: 2141-51.
57. Born Y, Fieseler L, Klumpp J et al. The tail-associated depolymerase of Erwinia amylovora phage L1 mediates host cell adsorption and enzymatic capsule removal, which can enhance infection by other phage. Environ Microbiol 2014; 16: 2168-80.
58. Lin TL, Hsieh PF, Huang YT et al. Isolation of a bacteriophage and its depolymerase specific for K1 capsule of Klebsiella pneumoniae: implication in typing and treatment. J Infect Dis 2014; 210: 1734-44.
59. Schmerer M, Molineux IJ, Bull JJ. Synergy as a rationale for phage therapy using phage cocktails. PeerJ 2014; 2: e590.
60. Henry M, Lavigne R, Debarbieux L. Predicting in vivo efficacy of therapeutic bacteriophages used to treat pulmonary infections. Antimicrob Agents Chemother 2013; 57: 5961-8.
61. Galtier M, De Sordi L, Maura D et al. Bacteriophages to reduce gut carriage of antibiotic resistant uropathogens with low impact on microbiota composition. Environ Microbiol 2016; doi:10.1111/1462-2920.13284.
62. Scholl D, Gebhart D, Williams SR et al. Genome sequence of E. coli O104:H4 leads to rapid development of a targeted antimicrobial agent against this emerging pathogen. PLoS One 2012; 7: e33637.
63. Yosef I, Manor M, Kiro R et al. Temperate and lytic bacteriophages programmed to sensitize and kill antibiotic-resistant bacteria. Proc Natl Acad Sci USA 2015; 112: 7267-72.
64. Lu TK, Collins JJ. Dispersing biofilms with engineered enzymatic bacteriophage. Proc Natl Acad Sci USA 2007; 104: 11197-202.
65. Ando H, Lemire S, Pires DP et al. Engineering modular viral scaffolds for targeted bacterial population editing. Cell Systems 2015; 1: 187-96.
66. Zankari E, Hasman H, Cosentino S et al. Identification of acquired antimicrobial resistance genes. J Antimicrob Chemother 2012; 67: 2640-4.